Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients.
Coronavirus
Myalgic encephalomyelitis/chronic fatigue syndrome
Natural killer cells
Post COVID-19 condition
SARS-CoV-2
Transient receptor potential melastatin 3
Whole-cell patch clamp electrophysiology
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
19 08 2022
19 08 2022
Historique:
received:
22
04
2022
accepted:
24
07
2022
entrez:
19
8
2022
pubmed:
20
8
2022
medline:
24
8
2022
Statut:
epublish
Résumé
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multisystemic condition associated with post-infectious onset, impaired natural killer (NK) cell cytotoxicity and impaired ion channel function, namely Transient Receptor Potential Melastatin 3 (TRPM3). Long-term effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has resulted in neurocognitive, immunological, gastrointestinal, and cardiovascular manifestations recently recognised as post coronavirus disease 2019 (COVID-19) condition. The symptomatology of ME/CFS overlaps significantly with post COVID-19; therefore, this research aimed to investigate TRPM3 ion channel function in post COVID-19 condition patients. Whole-cell patch-clamp technique was used to measure TRPM3 ion channel activity in isolated NK cells of N = 5 ME/CFS patients, N = 5 post COVID-19 patients, and N = 5 healthy controls (HC). The TRPM3 agonist, pregnenolone sulfate (PregS) was used to activate TRPM3 function, while ononetin was used as a TRPM3 antagonist. As reported in previous research, PregS-induced TRPM3 currents were significantly reduced in ME/CFS patients compared with HC (p = 0.0048). PregS-induced TRPM3 amplitude was significantly reduced in post COVID-19 condition compared with HC (p = 0.0039). Importantly, no significant difference was reported in ME/CFS patients compared with post COVID-19 condition as PregS-induced TRPM3 currents of post COVID-19 condition patients were similar of ME/CFS patients currents (p > 0.9999). Isolated NK cells from post COVID-19 condition and ME/CFS patients were resistant to ononetin and differed significantly with HC (p < 0.0001). The results of this investigation suggest that post COVID-19 condition patients may have impaired TRPM3 ion channel function and provide further evidence regarding the similarities between post COVID-19 condition and ME/CFS. Impaired TRPM3 channel activity in post COVID-19 condition patients suggest impaired ion mobilisation which may consequently impede cell function resulting in chronic post-infectious symptoms. Further investigation into TRPM3 function may elucidate the pathomechanism, provide a diagnostic and therapeutic target for post COVID-19 condition patients and commonalities with ME/CFS patients.
Sections du résumé
BACKGROUND
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multisystemic condition associated with post-infectious onset, impaired natural killer (NK) cell cytotoxicity and impaired ion channel function, namely Transient Receptor Potential Melastatin 3 (TRPM3). Long-term effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has resulted in neurocognitive, immunological, gastrointestinal, and cardiovascular manifestations recently recognised as post coronavirus disease 2019 (COVID-19) condition. The symptomatology of ME/CFS overlaps significantly with post COVID-19; therefore, this research aimed to investigate TRPM3 ion channel function in post COVID-19 condition patients.
METHODS
Whole-cell patch-clamp technique was used to measure TRPM3 ion channel activity in isolated NK cells of N = 5 ME/CFS patients, N = 5 post COVID-19 patients, and N = 5 healthy controls (HC). The TRPM3 agonist, pregnenolone sulfate (PregS) was used to activate TRPM3 function, while ononetin was used as a TRPM3 antagonist.
RESULTS
As reported in previous research, PregS-induced TRPM3 currents were significantly reduced in ME/CFS patients compared with HC (p = 0.0048). PregS-induced TRPM3 amplitude was significantly reduced in post COVID-19 condition compared with HC (p = 0.0039). Importantly, no significant difference was reported in ME/CFS patients compared with post COVID-19 condition as PregS-induced TRPM3 currents of post COVID-19 condition patients were similar of ME/CFS patients currents (p > 0.9999). Isolated NK cells from post COVID-19 condition and ME/CFS patients were resistant to ononetin and differed significantly with HC (p < 0.0001).
CONCLUSION
The results of this investigation suggest that post COVID-19 condition patients may have impaired TRPM3 ion channel function and provide further evidence regarding the similarities between post COVID-19 condition and ME/CFS. Impaired TRPM3 channel activity in post COVID-19 condition patients suggest impaired ion mobilisation which may consequently impede cell function resulting in chronic post-infectious symptoms. Further investigation into TRPM3 function may elucidate the pathomechanism, provide a diagnostic and therapeutic target for post COVID-19 condition patients and commonalities with ME/CFS patients.
Identifiants
pubmed: 35986236
doi: 10.1186/s10020-022-00528-y
pii: 10.1186/s10020-022-00528-y
pmc: PMC9388968
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
98Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2020 Nov 9;15(11):e0240784
pubmed: 33166287
Annu Rev Immunol. 1985;3:31-58
pubmed: 3904772
Am J Med. 1998 Sep 28;105(3A):27S-34S
pubmed: 9790479
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
J Neurovirol. 2021 Aug;27(4):631-637
pubmed: 34341960
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Auto Immun Highlights. 2013 Apr 16;4(3):69-80
pubmed: 26000145
Brain Behav Immun. 2012 Jan;26(1):24-31
pubmed: 21756995
Biol Res. 2016 May 31;49(1):27
pubmed: 27245705
Chem Biol Interact. 2021 Aug 25;345:109567
pubmed: 34166652
Nat Immunol. 2008 May;9(5):503-10
pubmed: 18425107
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Mol Med. 2019 Apr 23;25(1):14
pubmed: 31014226
Medicina (Kaunas). 2021 Feb 26;57(3):
pubmed: 33652622
J Transl Med. 2020 Feb 24;18(1):100
pubmed: 32093722
Nat Rev Immunol. 2022 Feb;22(2):112-123
pubmed: 34117484
Anaesth Crit Care Pain Med. 2021 Jun;40(3):100882
pubmed: 33965645
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
J Transl Med. 2011 May 28;9:81
pubmed: 21619669
Clin Exp Immunol. 2017 Feb;187(2):284-293
pubmed: 27727448
Cell. 2007 Dec 14;131(6):1047-58
pubmed: 18083096
Environ Health Perspect. 1999 Feb;107 Suppl 1:25-35
pubmed: 10229704
BMC Immunol. 2015 Jun 02;16:35
pubmed: 26032326
Clin Infect Dis. 2022 Apr 9;74(7):1191-1198
pubmed: 34223884
Cells. 2022 Jan 12;11(2):
pubmed: 35053369
Physiol Genomics. 2020 Nov 1;52(11):549-557
pubmed: 32991251
Biochim Biophys Acta. 2013 Jul;1833(7):1603-11
pubmed: 23220009
Immunol Rev. 2006 Dec;214:73-91
pubmed: 17100877
Pharmacol Res. 2017 Oct;124:92-99
pubmed: 28720517
Front Med (Lausanne). 2021 Jan 18;7:606824
pubmed: 33537329
Front Med (Lausanne). 2022 Feb 24;9:862953
pubmed: 35280890
Front Immunol. 2019 Oct 31;10:2545
pubmed: 31736966
Appl Clin Genet. 2016 Mar 31;9:39-47
pubmed: 27099524
Front Immunol. 2021 Jul 13;12:687806
pubmed: 34326841
Pathogens. 2021 Oct 30;10(11):
pubmed: 34832564
Autoimmun Rev. 2009 Feb;8(4):287-91
pubmed: 18801465
J Clin Med. 2021 Jul 06;10(14):
pubmed: 34300183
Qual Life Res. 2020 Jun;29(6):1521-1531
pubmed: 31970624
Med Hypotheses. 2020 Nov;144:110055
pubmed: 32758891
Brain Sci. 2021 Jun 08;11(6):
pubmed: 34201087
Blood. 2008 Aug 1;112(3):461-9
pubmed: 18650461
PLoS One. 2009 Dec 17;4(12):e8343
pubmed: 20020047
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Int J Mol Sci. 2020 Sep 01;21(17):
pubmed: 32883007
Ther Adv Infect Dis. 2021 Apr 20;8:20499361211009385
pubmed: 33959278
Rev Med Virol. 2022 Jul;32(4):e2315
pubmed: 34888989
Medicina (Kaunas). 2021 Sep 25;57(10):
pubmed: 34684049
Br J Pharmacol. 2013 Apr;168(8):1835-50
pubmed: 23190005
Medicina (Kaunas). 2021 Apr 26;57(5):
pubmed: 33925784
JAMA. 2021 May 18;325(19):2015-2016
pubmed: 33825846
Nat Protoc. 2006;1(6):2613-20
pubmed: 17406516
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Neurology. 2020 Sep 29;95(13):559-560
pubmed: 32788251
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
Syst Rev. 2019 Nov 14;8(1):279
pubmed: 31727160
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
J Immunol. 1987 Sep 15;139(6):1772-9
pubmed: 2957436
Clin Microbiol Infect. 2022 Mar;28(3):315-318
pubmed: 34826619
Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29
pubmed: 12838335
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
BMJ. 2006 Sep 16;333(7568):575
pubmed: 16950834
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
Int J Environ Res Public Health. 2021 Oct 11;18(20):
pubmed: 34682360
Mol Med. 2018 Aug 14;24(1):44
pubmed: 30134818
Curr Opin Virol. 2021 Aug;49:176-182
pubmed: 34217135
Cell. 2002 Mar 8;108(5):595-8
pubmed: 11893331